All In Biotech

Drug Trial Radar · NCT04573478

Atrasentan in Patients With IgA Nephropathy

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients With IgA Nephropathy at Risk of Progressive Loss of Renal Function

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

404

Actual

Start

Dec 11, 2020

Primary completion

Apr 14, 2028

Study completion Apr 14, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Oct 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Conditions

  • IgA Nephropathy
  • Immunoglobulin A Nephropathy

Interventions

  • AtrasentanDrug

    Film-coated tablet

  • PlaceboDrug

    Film-coated tablet

  • ZigakibartDrug

    pre-filled syringes with needle safety device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Double-blind period: Change in proteinuriaTime frame: Up to Week 36 or approximately 9 months
  2. Open-label period: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs)Time frame: From open-label baseline up to end of treatment visit, up to 48 weeks
  3. Open-label period: Number of Subjects With Adverse Events of Special Interest (AESI) Including Events of Fluid OverloadTime frame: From open-label baseline up to end of treatment visit, up to 48 weeks
  4. Substudy period: Number of subjects with TEAEsTime frame: From substudy baseline to end of treatment, up to 48 weeks
  5. Substudy period: Number of subjects with AESITime frame: From substudy baseline to end of treatment, up to 48 weeks

Locations

135 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Comprehensive Research Institute

    Alhambra, California

  • Kidney Disease Medical Group

    Glendale, California

  • Stanford University

    Stanford, California

  • University of Florida

    Gainesville, Florida

  • GA Nephrology Associates

    Lawrenceville, Georgia

  • NANI Research, LLC

    Hinsdale, Illinois

  • NANI Research, LLC

    Fort Wayne, Indiana

  • University of Louisville Physicians- Kidney Disease Program

    Louisville, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Intermed Consultants

    Minneapolis, Minnesota

  • Pelican Point Dialysis - DaVita Clinical Research

    Las Vegas, Nevada

  • Capital District Renal Physicians

    Clifton Park, New York

  • Mountain Kidney and Hypertension Associates

    Asheville, North Carolina

  • Brookview Hills Research Associates, LLC

    Winston-Salem, North Carolina

  • Lehigh Valley Hospital

    Bethlehem, Pennsylvania

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Liberty Research Center

    Dallas, Texas

  • El Paso Kidney Specialists

    El Paso, Texas

  • Nephrology Associates Of Northern Virginia

    Fairfax, Virginia

  • Swedish Health Services

    Seattle, Washington

  • CEMIC

    Buenos Aires, Argentina

  • Hospital Britanico de Buenos Aires

    Buenos Aires, Argentina

  • Clinica de Nefrologia Urologia y Enf. Cardiovasculares

    Santa Fe, Argentina

  • Centro Médico Ce.Re.Ca

    San Luis, San Luis Province, Argentina

  • Box Hill Hospital

    Box Hill, Australia

  • Royal Brisbane & Women's Hospital

    Brisbane, Australia

  • Monash Medical Centre

    Clayton, Australia

  • Renal Research

    Gosford, Australia

  • Nepean Hospital

    Kingswood, Australia

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia

  • Melbourne Renal Research Group

    Reservoir, Victoria, Australia

  • Sunshine Hospital

    Saint Albans, Victoria, Australia

  • Hospital das Clínicas Universidade Federal de Minas Gerais - UFMG

    Belo Horizonte, Brazil

  • Centro de Pesquisa Clinica do Brasil

    Brasília, Brazil

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil

  • Praxis Pesquisa Médica

    Santo André, Brazil

  • Hospital das Clinicas da Faculdade de Medicina da USP

    São Paulo, Brazil

  • Hospital do Rim Fundacao Oswaldo Ramos

    São Paulo, Brazil

  • Instituto Pró-Renal Brasil

    Curitiba, Paraná, Brazil

Showing 40 of 135 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.